...: Targeting the B-cell receptor pathway via ibrutinib, a specific inhibitor of Bruton’s tyrosine kinase, has shown marked clinical efficacy in treatment of patients with chronic lymphocytic leukemia (CLL), thus becoming a preferred first line option independent of risk factors. However, acquired resistance...

... to in the content or advertisements. 2023 Chronic lymphocytic leukemia Microenvironment B-cell receptor Nurse-like cells Chemokine receptors BTK PI3K Spleen tyrosine kinase Ibrutinib Chronic lymphocytic leukemia (CLL) is characterized by the expansion of monoclonal mature B lymphocytes...

...Shenmiao Yang; Rong Zhu; Nan Li; Yu Feng; Rui Zuo; Robert Peter Gale; Xiaojun Huang Introduction: Therapy of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with drugs such as ibrutinib and rituximab is often associated with immune suppression, opportunistic infections...

...Piotr Smolewski; Tadeusz Robak Recently, the use of novel targeted drugs has changed the treatment paradigms in chronic lymphocytic leukemia (CLL). Among the several drugs used for the management of relapsed/refractory (R/R) CLL, Bruton tyrosine kinase inhibitors (ibrutinib and acalabrutinib...

.... Active agents in the management of WM can be broadly classified as rituximab-alkylator combination therapy, proteasome inhibitor-based therapy, and Bruton’s tyrosine kinase inhibitor-based therapy. MYD88 L265P and CXCR4 genetic status are pivotal for tailoring treatment options. Ibrutinib is a suitable...

...Miri Schamroth Pravda; Nili Schamroth Pravda; Michael Lishner A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical...